Under the terms of the agreement, clinical researchers from University of California, San Diego (UCSD) will perform the Phase IIa study at the University’s General Clinical Research Center, and Raptor will provide funding and clinical supply of Cysteamine.
Raptor has previously acquired an exclusive, worldwide license to certain intellectual property and development rights from UCSD surrounding the use of cysteamine as a potential treatment for non-alcoholic steatohepatitis (NASH).
Ranjan Dohil, professor of pediatrics at UCSD, said: “The opportunity for delayed-release Cysteamine in NASH could become a potentially significant breakthrough for these patients.
“Our collaboration with Raptor allows us to run this clinical trial by leveraging the University’s resources and scientific capabilities with Raptor’s instrumental support in funding, providing drug supply, and offering formulation expertise.”